Analyst Issues Apple Inc $599 Stock Price Target, Vertex at Outperform, $38 Target on Fusion-IO

Apple Inc. (NASDAQ:AAPL): Jefferies believes Apple has the ability to maintain higher margins for longer than the market realizes given its supply chain initiatives. The firm thinks Apple can leverage its cash flow to fund suppliers’ manufacturing, which will mitigate margin pressures. Jefferies keeps a Buy rating on Apple shares with a $599 price target.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): After Vertex Pharmaceuticals’ Kalydeco was approved as a treatment for cystic fibrosis by the FDA two weeks ago, Bernstein reports that a significant number of patients seem likely to be treated by mid-year, beating the firm’s previous outlook. The firm expects the drug to be adopted rapidly and it maintains an Outperform rating on the stock.

Fusion-IO, Inc.(NYSE:FIO): Piper Jaffray believes the February 15 expiration of a lock-up period for 43.4M shares could bring selling pressure to Fusion-io. Piper said it would view a 10% drop in shares to around $20 as a strong buying opportunity. The firm continues to believe Fusion-io’s growth potential at Facebook and Apple is being significantly under-estimated by investors and reiterates an Overweight rating on the stock with a $38 price target.

Body Central Corp.(NASDAQ:BODY): Oppenheimer has confidence in what it sees as Body Central’s recession resistant business model and the firm raised its target on the stock to $31 from $27 while reiterating an Outperform rating.

Tesoro Corporation(NYSE:TSO): Oppenheimer remains upbeat about U.S. refining stocks, citing cost advantages due to the oversupply of crude oil from some sources and ongoing refining capacity rationalization. The firm believes that Tesoro (NYSE:TSO) and Valero (NYSE:VLO) have the best risk/reward ratios in the sector and the firm maintains Outperform ratings on both stocks.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

To contact the reporter on this story: Derek Hoffman at

To contact the editor responsible for this story: Damien Hoffman at